ImmunityBio, Inc. (NASDAQ:IBRX) Receives $12.60 Average Price Target from Brokerages

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) have received an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $12.60.

IBRX has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Piper Sandler lifted their price objective on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. Jefferies Financial Group lifted their price target on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, D. Boral Capital reissued a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a report on Monday, February 23rd.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced completion of enrollment in its pivotal randomized Phase 2 trial of ANKTIVA plus BCG vs BCG alone in BCG‑naïve NMIBC CIS — early completion reduces timeline uncertainty for a potential label‑expanding readout and supports commercial upside for ANKTIVA. Article Title
• Positive Sentiment: Analyst/valuation commentary highlights trial progress and strong ANKTIVA commercial momentum — positive narratives that can support higher forward earnings expectations and investor confidence. Article Title
• Neutral Sentiment: ImmunityBio will host a business update and review FY‑2025 financial results on March 3 — the call could drive volatility depending on revenue, guidance, and clinical updates management provides. Article Title
• Neutral Sentiment: HC Wainwright published a Q1 earnings forecast for ImmunityBio — analyst forecasts and any accompanying model changes will influence near‑term analyst sentiment and target‑price revisions. Article Title
• Negative Sentiment: Director Barry Simon sold 75,000 shares at an average price of $12.01 (disclosed Feb 24) — insider selling can be interpreted by some investors as a signal to reduce exposure, contributing to downward pressure. Article Title
• Negative Sentiment: Reports cite significant intraday profit‑taking (one article notes a ~17% drop after an intraday high) and coverage pointing to a ~7% decline — these articles reflect short‑term selling and headline‑driven volatility that can amplify swings in the stock. Article Title Article Title

ImmunityBio Price Performance

ImmunityBio stock opened at $9.78 on Wednesday. The firm has a market capitalization of $10.05 billion, a P/E ratio of -25.74 and a beta of -0.04. The stock has a fifty day moving average price of $5.27 and a two-hundred day moving average price of $3.39. ImmunityBio has a 52-week low of $1.83 and a 52-week high of $12.43.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter. On average, equities research analysts predict that ImmunityBio will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling

In other ImmunityBio news, Director Christobel Selecky sold 50,000 shares of the company’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Barry J. Simon sold 165,000 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares in the company, valued at $29,989,665.25. The trade was a 5.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 501,967 shares of company stock worth $4,466,412 over the last quarter. 69.48% of the stock is owned by company insiders.

Hedge Funds Weigh In On ImmunityBio

Several hedge funds have recently added to or reduced their stakes in IBRX. Walser Wealth Management Company A Ltd Liability Co bought a new stake in ImmunityBio during the 4th quarter worth about $59,000. Invesco Ltd. raised its stake in shares of ImmunityBio by 14.6% during the fourth quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock worth $362,000 after buying an additional 23,353 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in ImmunityBio by 69.7% in the fourth quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock valued at $660,000 after buying an additional 136,858 shares during the period. EP Wealth Advisors LLC bought a new position in ImmunityBio in the fourth quarter valued at approximately $35,000. Finally, Empowered Funds LLC acquired a new stake in ImmunityBio during the 4th quarter worth $28,000. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.